Day: November 13, 2021

Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Naïve Patients Shows Overall Response Rate (ORR) of 57% in Cervical Cancer, 60% in Melanoma with 30% Complete Response (CR) and 39% in Head and Neck Cancer SITC Update Conference Call and Webcast on Saturday, November 13 at 5:30 pm ET SAN CARLOS, Calif. and WASHINGTON, Nov. 13, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced clinical data for lifileucel in combination with pembrolizumab in patients with advanced cancers were presented in an oral session at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. A slide presentation is also available on the Iovance website. Clinical data...

NEWPORT NEWS, Va., Nov. 13, 2021 (GLOBE NEWSWIRE) — Huntington Ingalls Industries (NYSE: HII) today christened pre-commissioning unit New Jersey (SSN 796) at the company’s Newport News Shipbuilding division. “The christening is a Navy and shipbuilder tradition that celebrates the hard work and dedication of the women and men who are building this magnificent submarine, readying her for the next phase of construction, which includes launch, testing, sea trials and delivery to the Navy,” said Jennifer Boykin, president of Newport News Shipbuilding. “We commemorate these American builders during a challenging time in our nation’s history.” “When New Jersey joins the Navy’s fleet, she will deliver firepower for freedom, taking with her the skill of her shipbuilders, the spirit of her sponsor, the courage of her commander and crew and...

BELTSVILLE, Md., Nov. 13, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced new data from two clinical studies and one research study presented at the Society for Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C., and on a virtual platform. The data come from clinical studies evaluating NC318, a Siglec-15 (S15) antibody, and NC410, a fusion protein of LAIR-2, in patients with advanced/metastatic solid tumors, as well as from a research study evaluating NC410’s impact on T cell activation and myeloid cell polarization conducted in collaboration with the National Cancer Institute at the National Institutes of Health. “We are...

In an Expanded Access Program, advanced malignant PEComa patients who previously progressed on other mTOR inhibitors showed a 25% partial response rate and 63% clinical benefit rate when treated with nab-sirolimus In a final analysis from the AMPECT registrational trial in mTOR naïve patients with advanced malignant PEComa, results of a 2.5 year-follow-up showed a median duration of response exceeding 36 months and conversion of 2 patients to complete responses FYARRO™ has a November 26, 2021 PDUFA target dateLOS ANGELES, Nov. 13, 2021 (GLOBE NEWSWIRE) — Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced two oral presentations that were made related to its lead candidate,...

– NORSE TWO showed highly statistically significant, clinically relevant results consistent with historical ophthalmic bevacizumab data – Data support planned BLA submission with U.S. FDA in Q12022 ISELIN, N.J., Nov. 13, 2021 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today presented pivotal safety and efficacy data from the Phase 3 NORSE TWO trial for ONS-5010, an investigational ophthalmic formulation of bevacizumab for use in wet age-related macular degeneration (wet AMD) and other retinal indications, at the Retinal Subspecialty Day, AAO 2021 Annual Conference. The data presentation “Safety and Efficacy Results of ONS-5010, as Ophthalmic Bevacizumab,...

VANCOUVER, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) — Cashbox Ventures Ltd. (the “Company”) (CSE: CBOX) announces that it has entered into a Consulting Agreement whereby in exchange for services rendered over a twelve ‎month period, the Company issued a total of 1,750,000 common shares in the capital of ‎the Company (“Common Shares”), at a price of $0.045 per Common Shares. The Common Shares are ‎subject to a four-month hold period from the date of issuance in accordance with applicable securities ‎laws. With 50% of the Common Shares being subject to an additional 12 month hold from the date of issuance. About Cashbox Ventures Ltd. The Company recently divested all of its online platform assets. The business activities of the Company is expected to include the search and evaluation of new investment opportunities along...

VANCOUVER, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) — Ero Copper Corp. (TSX: ERO, NYSE: ERO) (the “Company”) announces that it has filed the 2021 Technical Report regarding the optimized Feasibility Study and updated Mineral Reserve and Mineral Resource estimate for its Boa Esperança Project, the results of which were announced on September 28, 2021. The Technical Report was prepared in accordance with the Canadian Securities Administrator’s National Instrument 43-101 – Standards of Disclosure for Mineral Projects, and can be found on the Company’s website (www.erocopper.com) and on SEDAR (www.sedar.com). ABOUT ERO COPPER CORP Ero Copper Corp, headquartered in Vancouver, B.C., is focused on copper production growth from the MCSA Mining Complex located in Bahia State, Brazil, with over 40 years of operating history...